Anixa Biosciences (Anixa Biosciences) Change In Payables And Accrued Expense : $0.42 Mil (TTM As of Jan. 2024)

View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Change In Payables And Accrued Expense?

Anixa Biosciences's Change In Payables And Accrued Expense for the quarter that ended in Jan. 2024 was $-0.37 Mil. It means Anixa Biosciences's Accounts Payable & Accrued Expense declined by $0.37 Mil from Oct. 2023 to Jan. 2024 .

Anixa Biosciences's Change In Payables And Accrued Expense for the fiscal year that ended in Oct. 2023 was $-0.02 Mil. It means Anixa Biosciences's Accounts Payable & Accrued Expense declined by $0.02 Mil from Oct. 2022 to Oct. 2023 .

Anixa Biosciences Change In Payables And Accrued Expense Historical Data

The historical data trend for Anixa Biosciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Change In Payables And Accrued Expense Chart

Anixa Biosciences Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.22

-0.35

0.10

0.76

-0.02

Anixa Biosciences Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-0.81	0.30	0.32	0.17	-0.37

Anixa Biosciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.42 Mil.

Anixa Biosciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Anixa Biosciences (Anixa Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118

Website

https://www.anixa.com

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Executives

Amit Kumar	director, officer: Chief Executive Officer	C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani	officer: COO & CFO	12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr	director	6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk	director	3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan	director
David Cavalier	director	C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams	director	C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox	director	929 NOWITA PLACE, VENICE CA 90291
Andrea Belz	director	1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender	officer: Chief Operating Officer	900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman	officer: President and CEO	C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop	officer: Sr. Vice President-Engineering	C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson	director	20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams	director	C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747